Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Ductal Carcinoma in Situ
Interventions: BIOLOGICAL: MUC1 Peptide Vaccine|DRUG: Hiltonol®|DRUG: Aromatase Inhibitor
Sponsor: Finn, Olivera, PhD
Collaborators: A Glimmer of Hope Foundation|Breast Cancer Research Foundation